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The United States is a leading nation in the development of synthetic biology, an emerging engineering
discipline to create, control and reprogram biological systems. With strategic investment from its gov-
ernment agencies, the U.S. has established numerous research centers and programs in synthetic biology,
enabling signiﬁcant advances in foundational tool development and practical applications ranging from
bioenergy, biomanufacturing, to biomedicine. To maintain its leadership in synthetic biology, U.S, has
conducted several roadmap studies to provide strategic visions and action recommendations. Here we
will provide a brief overview of the major research programs and roadmap studies of synthetic biology in
the U.S.
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Synthetic biology promises to provide sustainable solutions to
many grand challenges of the modern society via innovations in
agriculture, chemicals, pharmaceuticals, energy, and bioremedia-
tion [1e3,4,5]. Given its interdisciplinary nature, however, a
consensus deﬁnition of synthetic biology has yet been reached. Butratory, 600 South Mathews
ng by Elsevier B.V. on behalf of KeAat its core, the ﬁeld of synthetic biology centers on “design, con-
struction, and characterization of improved or novel biological
systems using engineering design principles” [6]. Although syn-
thetic biology is becoming a global research enterprise, the U.S. is
the leading nation in the world [7]. In 2000, two U.S. research
groups reported the creation of genetic oscillators and toggle
switches that function in an analogous manner to electrical circuits
[8,9], which marks the birth of the synthetic biology ﬁeld. Since
then, the U.S. government has been the biggest investor in this
emerging discipline, providing approximately $500 million to $1
billion research funding since 2005 [10,11], with a yearly spending
estimated at $140 million [12]. Many U.S. research centers focusingi Communications Co. This is an open access article under the CC BY-NC-ND license
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limited to Synthetic Biology Engineering Research Center (Syn-
berc), the Centers for Synthetic Biology at MIT and University of
California at San Francisco (UCSF), and the J. Craig Venter Institute.
Moreover, U.S. industry has also been investing heavily in the
medical and biotechnological applications of synthetic biology with
an expected market value of $10.8 billion by 2016 [13]. Exemplary
companies are from multinationals such as DuPont, BP, ExxonMo-
bil, to start-ups such as Synthetic Genomics, Amyris, Intrexon,
Ginkgo Bioworks, and Zymergen.
In this review, wewill brieﬂy summarize the research landscape
of synthetic biology in the U.S., focusing on major funding agencies
and research initiatives (Fig. 1 and Table 1). In particular, the
organizational structure and major accomplishments of Synberc,
the ﬁrst major U.S. synthetic biology research center, will be dis-
cussed in details. U.S. roadmap studies will also be discussed,
highlighting strategic plans to fully realize the potential of synthetic
biology and to maintain the U.S.’s leadership in this ﬁeld.
2. Major U.S. research agencies that fund synthetic biology
The funding from the U.S. government for synthetic biology is
spread among different agencies, lacking a coordinated govern-
ment funding mechanism [14]. Some of the most important federal
funders include the National Science Foundation (NSF), Depart-
ment of Energy (DOE), Department of Health & Human Services
(HHS, including National Institutes of Health (NIH)), Department of
Defense (DOD, including Defense Advanced Research Projects
Agency (DARPA)), the Navy, the Air Force, Department of Agricul-
ture (USDA), and National Aeronautics & Space Administration
(NASA) [10,11]. Dependent on the speciﬁc missions, different fed-
eral agencies have their own focuses in synthetic biology [15]. For
example, NSF aims to advance fundamental basic research, develop
novel engineered systems, educate a new cadre of students, and
support an emerging synthetic biology industry. DOE focuses on
the development and application of synthetic biology tools to
redesign plant, microbial and hybrid systems to manufacture bio-
fuels and bio-based products. NIH is interested in fundamental and
translational research areas where biomedical science and syn-
thetic biology overlap. DOD considers synthetic biology as one of
six high priority basic research topics because of its potentiallyFig. 1. A brief timeline of synthetic biology in the U.S. Blue box: major research achieveme
MAGE: multiplex automated genome engineering; SB1.0: Synthetic Biology 1.0; iGEM: In
Research Center; CBiRC: The Center for Biorenewable Chemicals; ARPA-E: Advanced Researtransformative impact in defense applications, including smart
sensing, novel materials, and medicine. For NASA, three focuses are
material resupply en route and at the destination for human mis-
sions, astrobiology, and next-generation aeronautics including the
use of biofuel and fuel additives. Moreover, synthetic biology may
also impact many USDA's strategic plans, such as expanding agri-
cultural markets, food safety, and nutrition and health. Herewewill
highlight four U.S. government agencies as major sponsors of
synthetic biology research, including NSF, DOE, DOD, and NIH
(Table 1).
NSF's Engineering Research Center (NRC) Program funded
Synberc in 2006, one of the earliest major research grants in syn-
thetic biology from the U.S. government. Synberc is a multi-
institutional research center (see the next session for details), and
its key members include faculty from University of California at
Berkeley (leading institution), Harvard, MIT, UCSF, and Stanford, as
well as a few industrial companies. Over 10 years, NSF has
committed $39 million to support Synberc [14,16], whose missions
are to (1) develop the foundational understanding and technologies
to build biological components and assemble them into integrated
systems to accomplish many particular tasks; (2) train a new cadre
of engineers who will specialize in engineering biology; and (3)
engage the public about the opportunities and challenges of engi-
neering biology (https://www.synberc.org/about). In 2008, a sec-
ond NSF ERC Center, Center for Biorenewable Chemicals (CBiRC)
was established at the Iowa State University, whose mission is to
“develop the fundamental knowledge and technology and the ac-
ademic and industrial partnerships needed to provide a foundation
for industrial chemical production to be transformed from a
petroleum-based industry to a renewable resource-based industry”
(http://www.cbirc.iastate.edu/overview/mission/). Furthermore,
NSF has been actively promoting international collaborations in
synthetic biology. In 2008, the NSF Division of Molecular and
Cellular Biosciences (MCB) co-organized an “Ideas Lab” or “Sandpit”
program in synthetic biology with the United Kingdom Physical
Science Research Council (EPSRC). In 2011, the second U.K.-U.S.
Ideas lab with a focus on improving photosynthesis was held
with a combined investment of $18 million. In 2014, NSF collabo-
rated with the U.K. Biotechnology and Biological Sciences Research
Council (BBSRC) to start a Pilot program in synthetic biology. To
reduce the barriers to work internationally, a simpliﬁed and ﬂexiblents; Red box: major research centers and programs; Green box: major roadmap studies.
ternational Genetically Engineered Machine; Synberc: Synthetic Biology Engineering
ch Projects Agency-Energy; DARPA: Defense Advanced Research Project Agency.
Table 1
Major synthetic biology centers/initiatives in the U.S.
Agency Program name Lead institution Program duration Funding (million dollar)
NSF Synthetic Biology Engineering Research Center
(SynBERC)
UC Berkeley 2006e2016 39
DOE DOE Bioenergy Science Center Oak Ridge National Lab 2007e2018 250
DOE DOE Great Lakes Bioenergy Research Center U Wisconsin/Michigan State University 2007e2018 250
DOE DOE Joint BioEnergy Institute Lawrence Berkeley National Lab 2007e2018 250
NIH Center for Systems and Synthetic Biology UC San Francisco 2011e2016 15
NIH MIT Center for Integrative Synthetic Biology MIT 2013e2017 12
NIH Genomes-to-Natural Products program Rockefeller University/Stanford 2014e2019 20
DOD-DARPA Living Foundries: ATCG MIT/U Texas/Caltech/J Craig Venter Institute 2011e2014 35
DOD-DARPA Living Foundries: 1000 Molecules UC Berkeley/MIT/Harvard/UIUC/U Colorado/
Zymergen/Amyris
2013-now 110
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only one of the partner agencies is necessary for the successfully
proposals to be funded by both NSF and BBSRC. In addition to the
collaborations between the U.S. and U.K., NSF initiated a bilateral
funding program, Metabolism: for a Low Carbon Society, with the
Japan Science and Technology (JST) with $12 million grants in 2011.
Other than the research centers and special programs, NSF also
provides smaller grants that have come out of unsolicited pro-
posals, adding up to $55 million funding in synthetic biology
annually [14].
DOE has been estimated to invest the most research funding in
synthetic biology among U.S. government agencies (over $700
million), primarily in the area of bioenergy [14]. Four major syn-
thetic biology programs are supported by DOE, including Joint
Genome Institute, Genomic Sciences Program, Bioenergy Research
Centers, and Advanced Research Projects Agency-Energy (ARPA-E).
In particular, DOE's Bioenergy Research Centers program has
committed $750million to support three centers for ten years since
2007, with the aim to “better understand the biological mecha-
nisms underlying biofuel production so that those mechanisms can
be redesigned, improved, and used to develop novel, efﬁcient,
bioenergy strategies that can be replicated on a mass scale” [14].
The three centers are BioEnergy Science Center (BESC, Oak Ridge,
Tennessee), Great Lakes Bioenergy Research Center (GLBRC, Madi-
son, Wisconsin), and Joint BioEnergy Institute (JBEI, Emeryville,
California). These centers emphasize on different research areas of
bioenergy, with BESC focusing on poplar and switchgrass crops and
their biomass formation, structure and recalcitrance, GLBRC
focusing on plant ﬁber breakdown to maximize production of
starches and oils, and JBEI focusing on microbial synthesis of
advanced biofuels. On the other hand, for ARPA-E, its creation was
recommended by a report from U.S. National Academies as a
response to the request from the U.S. congress to “identify the most
urgent challenges the U.S. faces in maintaining leadership in key
areas of science and technology.” ARPA-E was authorized by The
America COMPETES Act in 2007, and is modeled after the DOD's
DARPA, whose mission is to prevent unforeseen attack from
negatively impacting U.S. national security and to ensure strategic
military advantage for the U.S. military through technological su-
periority. ARPA-E funds “high-risk, high-impact” research pro-
grams to develop transformational energy technologies, and
exemplary projects that are related to synthetic biology include
“Synthetic Gene Circuits to Enhance Production of Transgenic Bio-
energy Crops”, “Synthetic Methylotrophy to Liquid Fuel”, “Anaer-
obic Bioconversion of Methane to Methanol”, and “Synthetic
Biology, Protein Engineering, and Semi-Biological Photocatalysis to
Convert Methane to n-Butanol” [10].
In DOD, synthetic biology is identiﬁed as one of the six high-
interest basic science areas [15]. Although most DOD research is
classiﬁed, public reports indicate there are 18 synthetic biologyprojects within Naval Biosciences and Biocentric Technology Pro-
gram [11]. The DOD's Ofﬁce of Naval Research (ONR) has invested
about $5 million per year in synthetic biology research “to develop
engineered organisms to produce, deliver, detect, and/or respond to
target compounds or signals, and that can communicate with non-
living devices, in support of future naval capabilities.” Represen-
tative projects that are awarded include “Powerful Combinatorial
Sensors to Program Microbes” and “Multiplexed Pathway and Or-
ganism Engineering” [11]. Furthermore, DARPR has initiated two
Living Foundries programsdLiving Foundries: Advanced Tools and
Capabilities for Generalizable Platforms (ATCG) and Living
Foundries: 1000 Molecules (Table 1) [14]. The goal of the Living
Foundries initiative is “to create a revolutionary, biologically based
manufacturing platform to provide access to new materials, capa-
bilities and manufacturing paradigms” [14]. With a budget of about
$35million from 2012 to 2014, the Living Foundries: ATCG program
aims to accelerate the biological design-build-test-learn cycle by at
least 10 fold in both time and cost via the development of next-
generation tools. Building upon the technological advancements
under ATCG, the Living Foundries: 1000 Molecules program seeks
to create a scalable and integrated infrastructure for rapid design
and prototyping of engineered biological systems. With a $110
million budget, the 1000 Molecules program expects a milestone
demonstration to generate 1000 novel chemical molecules of
relevance to the DOD, such as chemical building blocks towards
radical new materials [14]. To achieve this speciﬁc goal and more
broadly, to leverage biology as a technology platform to pursue
transformative applications across chemicals, materials, sensing
capabilities and therapeutics, the 1000 Molecules program seeks
the development of “a fully integrated, rapid design and proto-
typing infrastructure that spans design tools, scalable, automated,
and parallelized design fabrication, and high-throughput design
evaluation and validation” [17]. The overall objective is to automate
and scale-up the design-build-test-learn cycles to streamline bio-
logical engineering. Six teams, including University of California at
Berkeley, MIT, Harvard, University of Colorado, University of Illinois
at Urbana-Champaign (UIUC), and a start-up company Zymergen,
were selected for Task Area 1 phase funding (Table 1). MIT and
Zymergen, as well as another company Amyris, were selected for
Task Area 2 phase funding with around $35 million per team
(Table 1).
NIH, an organization of HHS, supports extramural research of
synthetic biology with biomedical and healthcare applications via
investigator-initiated grants, which was estimated to be more than
$50 million during 2005e2010 [10]. As NIH operates as 27 separate
institutes with individual research agenda, most NIH grants in
synthetic biology are small ones awarded to individual researchers,
but NIH also funded a few large center-level grants including the
UCSF Center for Systems & Synthetic Biology, MIT Center for Inte-
grative Synthetic Biology, the Johns Hopkins University School of
T. Si, H. Zhao / Synthetic and Systems Biotechnology 1 (2016) 258e264 261Medicine Center for Systems Biology of Retrotransposition, and the
Stanford Center for Systems Biology (Table 1) [14]. In particular, the
UCSF center focuses on the principles and architectural features
involved in common cellular processing behaviors and use this
information to engineer synthetic circuits that can trigger desirable
cellular responses to external cues, making them potentially useful
in biotechnology and biomedicine. The MIT center explores using
synthetic, RNA-based circuits to sense and destroy cancerous cells;
programming the differentiation of stem cells to generate insulin-
producing beta-islet cells for diabetes; and engineering ap-
proaches to target antibiotic-resistant bacteria. Moreover, NIH has
recently awarded $20 million between 2014 and 2019 to Rock-
efeller University and Stanford University under the Genomes-to-
Natural Products program (Table 1), aiming to apply “well-inte-
grated genomics, synthetic biology, and bioinformatics expertise to
develop innovative, high-throughput, and broadly applicable
genome-based methods for natural products discovery that over-
come technical barriers and ﬁll knowledge gaps for translation of
genetic information into chemical information” (http://grants.nih.
gov/grants/guide/rfa-ﬁles/RFA-GM-14-002.html).
On a separate note, the involvement of government agencies in
commercial development of synthetic biology is primarily indirect
[15]. For example, federal investments in synthetic biology research
contribute foundational knowledge and technological develop-
ment to facilitate commercial applications in platform organisms,
process pathways and related biotechnologies [15]. Moreover,
through government funded synthetic biology research, a new
generation of scientists are trained at the interface of systems
biology, chemical engineering, molecular biology, and bioinfor-
matics, and the skill sets are critical in applied synthetic biology
R&D but rarely acquired in traditional research programs [15].
There are also instances where the federal agencies directly fund
the private sectors in synthetic biology applications. The Small
Business Innovation Research (SBIR) and Small Business Technol-
ogy Transfer (STTR) programs provide grants to domestic small
businesses in commercialization of innovations derived from
federally funded research (https://www.sbir.gov/). Synthetic
biology-related SBIR/STTR solicitations from NSF, DOD, and NASA
seek proposals in the area of metabolic engineering, large DNA
constructs, microbiome, space exploration, etc. Furthermore, start-
up synthetic biology companies are also awarded federal funding in
their early stage [14]. For instance, Solazyme received a $21 million
grant from DOE to develop algae-based biofuels. Modular Genetics
was awarded a $200 K NSF Rapid Response grant for bioremedia-
tion in the 2010 Deepwater Horizon oil spill in the Gulf of Mexico.
Amyris, Zymergen, and Twist Bioscience received $35, 35 and 5
million from DOD, respectively, through the DARPR Living
Foundries: 1000 molecules program.
In sum, signiﬁcant ﬁnancial support across many U.S. agencies is
steadily growing for synthetic biology and the major research
programs have laid the groundwork for synthetic biology, including
fundamental understanding and tools to design, build and test
biological systems at all scales, a new cadre of scientists and engi-
neers specialized in synthetic biology, and a fast-growing industry
for a wide-range of applications. As multiple U.S. government
agencies are investing in synthetic biology, it is increasingly
recognized that good interagency communication and coordination
is critical to build synergies, leverage investments, and minimize
duplication or overlap, but currently the U.S. still lacks a national
infrastructure to coordinate research funding in this area [14,15].
Although the U.S. White House Ofﬁce of Science and Technology
Policy (OSTP) is increasingly trying to identify collaboration op-
portunities across different government agencies in synthetic
biology and related disciplines (systems biology, bioprocessing, and
biomanufacturing), in the near future it is unlikely to witness acoordinated national effort on the scale of the U.S. National Nano-
technology Initiative [14].
3. Synberc
Since its establishment in 2006, Synberc has helped to shape the
global research agenda for synthetic biology, by developing foun-
dational technologies, convening academic and industrial re-
searchers, and training many of the leading investigators in this
ﬁeld. Synberc is considered an effective model to explore and align
biotechnology activities with public needs via dialogue, research
and education [14,16]. In particular, recognizing synthetic biology
would require a collective rather than individual effort, Synberc
was established as a “virtual” center to establish a common
research and education infrastructure. Synberc uses a distributed
organizational structure in its leadership team, including a Center
Director (Jay Keasling), a Deputy Director (Wendell Lim), Directors
specialized in various areas (administrative, industrial collabora-
tion, education and training, and bioethics), and support staff. Each
research direction is also led by a scientiﬁc leader chosen across the
partner institutions. Synberc has a headquarter at UC Berkeley, and
three core facilities in Synthetic Microbial Characterization,
Computational Design, and Registry of Standard Biological Parts.
The participating institutions also formed two core centers in San
Francisco and Boston areas based on geographic locations. Finan-
cially, in addition to the NSF center grant, which accounts for 87% of
the total funding, Synberc also assists participating investigators to
procure additional funding from federal programs, state opportu-
nities, targeted private foundations and industry. In retrospect, the
“virtual” center mechanism is considered essential to develop the
synthetic biology community, as well as to establish intellectual
foundation and commercialization for the ﬁeld [14,16], by bringing
researchers from allied ﬁelds in sustained conversation, forming a
nucleus of interdisciplinary leaders for major proof-of-concept
programs, and enabling the foundation for industry-academia
collaboration. These achievements may be simply beyond the
capability of any individual laboratory alone.
Synberc pursues three major programmatic areas: Research,
Education, and Practices (The Synthetic Biology Security, Policy and
Ethics Program) [14,16]. The Research program aims to build and
assemble standardized biological components into an integrated
system to accomplish a particular task [14]. This goal is achieved
through three “thrust” areas, including Parts and Part Composition,
Device and Device Composition, and Chassis Design, Construction
and Characterization. The main principles behind these research
areas are standardization, models and methods, composability,
evolution and open access. Two Testbed applications, a bacterium
capable of moving to and attacking a chemical or biological entity,
as well as a microbial drug factory to produce a large range of
natural and un-natural products, are used as vehicles to drive
development of the research thrusts [14]. These research activities
have provided fundamental advances in synthetic biology, such as
“highly multiplexed genome engineering, rational design tools,
computer programs, standardized parts and registries, biofabs, and
engineered cell traits” [14], which collectively have substantially
reduced time and cost of biological engineering with increased
predictability. As of April 2015, Synberc has produced 364 papers in
peer-reviewed journals, 88 patent applications (9 patents awarded,
5 licenses issued), 71 graduated PhDs, 8 start-up companies, and
$88.6 million direct associated project funding (personal commu-
nication). Moreover, many large-scale synthetic biology centers are
started around Synberc, such as the ones in MIT, UCSF, and UC
Berkeley. For Education, Synberc offers a series of programs tar-
geting different audiences, including graduate and undergraduate
students, the general public, policymakers, and K-12 students.
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as outreach events cumulatively covering more than 53,000 stu-
dents, teachers and others. Notably, Synberc is one of the main
supporters for iGEM (International Genetically Engineered Ma-
chine Competition), which is now a global synthetic biology edu-
cation program for undergraduate students. For the Practices
program, it examines and addresses safety, security, responsible
conduct of research, intellectual property, and ethical, legal, and
social implications of synthetic biology [14]. In addition to the
above three areas, Synberc is required by NSF to develop a strong
relationship with industry. In its Industrial Advisory Board (IAB),
Synberc includes 29 established and start-up companies with a
wide range of focused markets, such as industrial biotechnology,
health care and nutrition, software and service, and agriculture. The
IAB provides regular feedback to Synberc on its research programs
and directions, and participates in the development of white papers
with the community. Some IAB members also sponsor Synberc
activities and support student involvement through internship [14].
The NSF Engineering Research Centers (ERC) program, through
which Synberc is funded and established, publishes program
evaluations and case studies of program impact for its awarded
centers (http://erc-assoc.org/). These reports assess the ERC pro-
grams from the following aspects: strategic planning, undergrad-
uate and graduate education, institutional and cultural change on
the home institutions, post-graduation status, interaction with in-
dustry, and economic impact. So far, Synberc is only mentioned in
one public report, “ERC-Generated Commercialized Products, Pro-
cesses, and Startups”, which has listed Amyris and LS9, two Synberc
spinoff companies, as commercialization successes for semi-
synthetic artemisinic acid production and rapid genomic engi-
neering for biofuel production, respectively. In addition, on the ERC
website, the achievements of the ERC centers are classiﬁed into
Research Advances, Technology Translation and Innovation, and
Education and Outreach, whereby the impactful accomplishments
of Synberc are also listed (http://erc-assoc.org/achievements/by_
center?id¼13).
It is the policy of NSF to cease funding for ERC programs at the
end of the ten-year cooperative agreement with the expectation
that these centers may become self-sustaining [18], especially
considering the strong emphasis on industrial collaboration and
technology transfer in the ERC programs. In 2016, as the 10-year
support from NSF is discontinued, Synberc has been transformed
into the Engineering Biology Research Consortium (EBRC) as an
independent non-proﬁt organization (http://ebrc.org). The vision
of this new organization is “to be the leading organization in the US
bringing together the synthetic biology community to provide the
future vision for synthetic biology, catalyze leading-edge research
and education programs, and promote dialogue about synthetic
biology among policy-makers and other members of the public.”
(https://www.synberc.org/ebrc). As EBRC was newly launched,
there is not much public information available for its operational
details, except for a few FAQs that brieﬂy explain EBRC's research
missions, Board of Directors, membership, and funding plans
(http://ebrc.org/about/faq/).
4. U.S. roadmap studies for synthetic biology
Recognizing the strategic importance of synthetic biology, many
U.S. public agencies have published roadmap studies to provide
visions and recommendations to address the key challenges and
deliver important applications of synthetic biology. Given the
speciﬁc missions of various agencies, these roadmap reports have
different focuses such as bioeconomy, bioenergy, bio-
manufacturing, biosecurity, and social implications.
In 2012, the National Bioeconomy Blueprint was released by theU.S. White House Ofﬁce of Science & Technology Policy (OSTP) to
“lay out strategic objectives that address the key elements to help
realize the full potential of the U.S. bioeconomy and to highlight
early achievements toward those objectives.” Although not
addressed speciﬁcally to synthetic biology, the ﬁve strategic ob-
jectives outlined in the report are highly relevantdincreasing R&D,
facilitating commercialization, streamlining regulation, increasing
education, and broadening scientiﬁc knowledge [19]. Moreover, a
subsequent report, Putting the Bioeconomy Blueprint to Work, out-
lined several immediate action steps that depend on advancement
in synthetic biology [20], such as building support for biofuel
production facilities to create jobs and expand the use of alternative
energy, training the power of induced pluripotent cell technology
on blood-related and neurological diseases, growing the economy
and rural jobs by supporting biomass production, collaborating to
reduce the need for nitrogen fertilizer inputs, and improving na-
tional security through biological research.
In July 2013, DOE prepared a Report to Congress: Synthetic Biology
in response to the request from the U.S. congress for “a compre-
hensive synthetic biology plan for federally supported research and
development activities that will support the energy and environ-
mental missions of the Department and enable a competitive
synthetic biology industry in the United States.” In this report, the
current state, future R&D needs, and federal research programs of
synthetic biology in the U.S. were summarized [15]. Enhanced co-
ordination between federal agencies to establish a comprehensive
effort in synthetic biology on a national level was recommended.
Moreover, this report identiﬁed the need for open information
exchange among public and private stakeholders, recommending
the development of standards for information, tools and compo-
nent parts and databases speciﬁc to synthetic biology. Three key
challenges for synthetic biology research were identiﬁed:
1. Methods and Technologies: Genome Scale Engineering Tools,
DNA Synthesis and Assembly, Analytical Tools
2. Platform Development: Biological Design Principles, Geneti-
cally Tractable Organisms/Chassis, Minimal Cell and in vitro
Systems, Tools for Plant Systems, Biocontainment Mechanisms
3. Computational Tools and Bioinformatics Resources: Compu-
tational Tools, Information Standards and Databases
As NSF's 10-year ﬁnancial commitment for Synberc ends in
2016, Synberc started a sustainability initiative in 2013 to develop a
strategic action plan with the aim “to extend the efforts begun by
Synberc and advance the ﬁeld of synthetic biology in the U.S.”
[14,16]. In addition to identify an operational plan toward a self-
sustaining future for Synberc, this initiative also seeks to provide
a shared infrastructure for the U.S. synthetic biology research
community in an environment of uncertain funding sources [14,16].
The ﬁnal report recommended the evolution of Synberc into a new
type of research center (“NewOrg”) with a mission to “develop,
promote and sustain biologically engineered solutions for a sus-
tainable global future with a focus on energy, agriculture, the
environment, and health.” In 2016, EBRC was launched as the
successor organization to Synberc. Although comprehensive in-
formation about EBRC has yet been released publicly, EBRC's vision,
missions, goals and plans have been outlined at the Synberc's
website (www.synberc.org/ebrc). Moreover, the sustainability
initiative report also proposed to perform a U.S. Synthetic Biology
Strategic Roadmap to address the following aspects [16]:
1. Research. a. Development of a Research Agenda with both
short- and long-term goals and a shared vision for achieving
outcomes consistent with public values and priorities. b.
Renewed, sustained investment in foundational tools and
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methods in the design-build-test cycle, and developing a
context-independent framework for integrating biological
components. c. Deﬁnition of large, multi-institutional research
projects with clear connections to commercial applications.
2. Public Infrastructure and Scaling. This includes professional-
scale registries, repositories, foundries, an advanced research
center, novel practices for making IP available to practitioners at
fair and reasonable terms (including free use via the public
domain), and standards in the context of an open resource fa-
cility available to the entire synthetic biology community to
work together in a pre-competitive environment.
3. Policy Development and Regulation to address potential se-
curity, safety, environmental and economic effects of synthetic
biology, establish regulatory jurisdiction, reduce regulatory
uncertainty, and address ethical, legal and social concerns sur-
rounding the research.
4. Industry/Academic Collaborations to align strategic research
aims, spur economic development, promote commercialization
of academic research, and encourage new start-up ventures.
5. Education and Leadership Development e creating tomor-
row's practitioners, educators, legislators, and regulators, and a
workforce that is diverse in socioeconomic background, disci-
pline, and thought.
6. Public Engagement to educate, inform, learn, and engage in a
robust debate about how to create science that is toward in the
greatest public interest, and carried out in a transparent and
democratic manner.
7. Connecting with the Global Community to ensure efﬁcient,
equitable adoption of synthetic biology technologies and dis-
tribution of products throughout the world, and to participate in
international discussion about the regulation and distribution of
the science.
In January 2015, DOD published a report titled Technical
Assessment: Synthetic Biology. It was released by DOD's Ofﬁce of
Technical Intelligence (OTI), whose mission is to provide “holistic,
defense-relevant insights into emerging and potentially disruptive
technology to enable U.S. and mitigate adversary technological
surprises.” Four major defense applications of synthetic bio-
logydcommodity and specialty materials, sensing, medical and
human performance modiﬁcation, and biological and chemical
defensedwere identiﬁed, and practical R&D steps were recom-
mended to advance these applications [21]. In addition, human
capital development was highlighted to train DOD personnel with
deep knowledge of synthetic biology.
In March 2015, the U.S. National Academies of Sciences, Engi-
neering and Medicine released the report Industrialization of
Biology: A Roadmap to Accelerate the Advanced Manufacturing of
Chemicals. Recognizing industrial biotechnology as an important
and growing part of the U.S. economy ($350 billion or 2% of U.S. GDP
in 2012), this report aims to develop a technical roadmap of sci-
entiﬁc and engineering advances to fully realize the vision of a
future that “biological synthesis and engineering and chemical
synthesis and engineering are on par with one another for chemical
manufacturing” [22]. Six technical areas are outlined, and synthetic
biology is identiﬁed at the center of technological development for
all areas including:
1. Feedstocks and Pre-Processing: enhancing the availability and
reliability of economic and environmentally sustainable feed-
stocks of diverse sources
2. Fermentation and Processing: Improving mass and heat
transfer, continuous product removal; more extensive use of co-
cultures, co-products, and co-substrates; Developing predictivecomputational tools based on small-scale experimental models
that realistically predict performance at scale
3. Design Toolchain: An integrated, predictive, forward design
framework across all scales of the biomanufacturing process.
4. Organism: Pathways: fast development of enzymes with
desirable catalytic activity and speciﬁc activity
5. Organism: Chassis: Enabling technologies to enhance genetic
manipulation; Expanding the collection of domesticated mi-
crobial and cell-free platforms; Cultivating robust strains with
stable performances
6. Test and Measurement: Rapidly, routinely, and reproducibly
measuring pathway function and cellular physiology with
decreased cost and increased throughput.
In addition to the research aspects, the importance of social,
ethical and legal implications of synthetic biology has been
recognized but not systematically addressed in most of the above
roadmap studies. For related issues, in 2010, the U.S. president
Barack Obama appointed Presidential Commission to study
bioethical issues to “review the developing ﬁeld of synthetic
biology and identify appropriate ethical boundaries to maximize
public beneﬁts and minimize risks.” The Commission published a
report, New Directions: The Ethics of Synthetic Biology & Emerging
Technologies, which identiﬁed ﬁve criteria for assessing the social
implications of synthetic biology: public beneﬁcence, responsible
stewardship, intellectual freedom and responsibility, democratic
deliberation, and justice and fairness [23]. For the legal and regu-
latory aspects of synthetic biology, the J. Craig Venter Institute
released a report in 2014, Synthetic Biology and the U.S. Biotech-
nology Regulatory Systems: Challenges and Options, to address “how
well the current U.S. regulatory system for genetically engineered
products is equipped to handle the near-term introduction of or-
ganisms engineered using synthetic biology.” Key challenges and
policy options were analyzed, focusing on the engineered organ-
isms that are used or grown directly in the environment, outside a
contained facility [24].
Common to all these U.S. roadmap reports, the strategic signif-
icance of synthetic biology and increasing competitions from other
countries are well recognized. Although speciﬁc technical recom-
mendations are provided given the different scopes of these
studies, taking systematic approaches across different disciplines
and public/private sections is a recurring theme to fully realize the
potential of synthetic biology. Due to lack of an overarching funding
or governance plan from the U.S. government [12], it remains un-
clear to what extent these roadmap studies has impacted the
funding landscape of synthetic biology. Within individual agencies
(DOD and DOE, in particular), however, a general match is observed
between the funding agenda and technical recommendations in
the roadmaps published by the corresponding agencies.
5. Conclusion
The U.S. has been pioneering synthetic biology research for
more than 15 years since the inception of this ﬁeld. As a nation that
has so far invested the largest public research funding in synthetic
biology, the U.S. continues to increase the investment rapidly,
especially in the form of large-scale integrated programs (Table 1),
in the hope to maintain its leadership and foster transformative
breakthroughs. Although a national initiative is not expected in the
near future [14], U.S. roadmap studies in synthetic biology have
been performed to recommend R&D strategies to tackle key chal-
lenges and enable innovative applications. It is anticipated that
with the sustainable strategic investment from the U.S. government
agencies, synthetic biology will continue to thrive in both basic and
applied research in the U.S.
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